Research programme: antibacterials - Provid
Latest Information Update: 04 Apr 2008
At a glance
- Originator Provid Pharmaceuticals
- Mechanism of Action DNA-directed RNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Jan 2004 Preclinical trials in Bacterial infections in USA (unspecified route)